Please assess the completion status of the following clinical trial:

Trial Title: Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Newly diagnosed MDS patients aged 21 to 65 years belonging to any of the following categories: refractory cytopenia with multilineage dysplasia (RCMD) with or without ringed sideroblasts (i.e. RCMD and RCMD-RS), refractory anemia with excess blasts-1 (RAEB-1) or RAEB-2 if the prognostic scores are IPSS (international prognostic scoring system) Int-2 or IPSS-high or with WPSS (WHO prognostic scoring system) 3 and above~2. Therapy-related MDS with IPSS Int-2 and above or WPSS 3~3. Acceptable cardiac function MUGA or Echocardiography left ventricular ejection fraction of 40% and above~4. Acceptable lung function: FEV1\>70% predicted, DLCO\>60% predicted~5. Acceptable renal function: CCT \> 50ml/min~6. Acceptable liver function: abnormalities in bilirubin or transaminases not \> 2times upper limit of normal~7. Performance status of ECOG 2 or HCT-specific Comorbidity Index \< 3~Exclusion Criteria:~1. Any co-morbidity other than MDS which limits life-expectancy to \<3mth~2. Diagnosis of other active cancer other than squamous cell carcinoma, basal cell carcinoma or carcinoma-in-situ 1 or 2 of the cervix~3. Presence of active infections not under control~4. Receipt of 5-azacytidine or other induction chemotherapy for MDS/AML~5. Patients not keen to explore allogeneic HCT as part of curative treatment plan~6. Pregnancy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Decitabine 20mg/m\^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).